Summit Therapeutics Inc (NASDAQ:SMMT) shares are plummeting after reporting its first‑quarter financial results. Here’s what you should know.
- Summit Therapeutics stock is feeling bearish pressure. Why are SMMT shares down?
While the company delivered a better‑than‑expected Non‑GAAP EPS loss of 15 cents versus the 18 cents estimate, the rest of the update highlighted rising spending, widening losses, and a lack of near‑term clinical catalysts.
Financial Results Pressured Sentiment
The non‑GAAP net loss widened to $(116.6) million from $(51.8) million a year earlier. Non‑GAAP operating expenses rose sharply to $122.4 million, more than doubling from the prior year as the company expanded clinical …